Topic: How To Invest

Q: Pat: How do you assess the prospects of TrovaGene? Thank you.

Article Excerpt

A: TrovaGene Inc., $0.76, symbol TROV on Nasdaq (Shares outstanding: 31.0 million; Market cap: $25.4 million; www.trovagene.com), develops and sells non-invasive, liquid biopsy tests to detect and monitor serious illnesses, including cancer. The company believes that its exclusive technology positions it to benefit from a change in the way diagnostic medicine is practiced. TrovaGene uses simple, non-invasive sampling and analysis of nucleic acids in urine and blood. It believes that current monitoring tools, such as imaging procedures, tissue biopsy and circulating tumour cell testing, fail to detect cancer mutations as quickly as they should. The company also believes that its own technology will improve testing and lead to better management of cancer and other serious illnesses. TrovaGene now owns 120 issued patents and has over 60 pending patent applications in the U.S. and elsewhere. Its patents include medical applications to detect cell-free nucleic acids in urine and blood and to promote their use in specific areas of medicine. Those areas include oncology,…